

Id2 expression delineates differential checkpoints in the genetic program of CD8 α^+ and CD103 $^+$ dendritic cell lineages

This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.

Jacob T Jackson¹, Yifang Hu², Ruijie Liu²,
Frederick Masson¹, Angela D'Amico¹,
Sebastian Carotta¹, Annie Xin^{1,3},
Mary J Camilleri¹, Adele M Mount¹,
Axel Kallies^{1,3}, Li Wu^{1,3}, Gordon K Smyth^{2,4},
Stephen L Nutt^{1,3,*} and Gabrielle T Belz^{1,3,*}

¹Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia, ²Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia, ³Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia and ⁴Department of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia

Dendritic cells (DCs) have critical roles in the induction of the adaptive immune response. The transcription factors Id2, Batf3 and Irf-8 are required for many aspects of murine DC differentiation including development of CD8 α^+ and CD103 $^+$ DCs. How they regulate DC subset specification is not completely understood. Using an Id2-GFP reporter system, we show that Id2 is broadly expressed in all cDC subsets with the highest expression in CD103 $^+$ and CD8 α^+ lineages. Notably, CD103 $^+$ DCs were the only DC able to constitutively cross-present cell-associated antigens *in vitro*. Irf-8 deficiency affected loss of development of virtually all conventional DCs (cDCs) while Batf3 deficiency resulted in the development of Sirp- α^- DCs that had impaired survival. Exposure to GM-CSF during differentiation induced expression of CD103 in Id2-GFP $^+$ DCs. It did not restore cross-presenting capacity to Batf3 $^{-/-}$ or CD103 $^-$ Sirp- α^- DCs *in vitro*. Thus, Irf-8 and Batf3 regulate distinct stages in DC differentiation during the development of cDCs. Genetic mapping DC subset differentiation using Id2-GFP may have broad implications in understanding the interplay of DC subsets during protective and pathological immune responses.

The EMBO Journal (2011) 30, 2690–2704. doi:10.1038/emboj.2011.163; Published online 17 May 2011

Subject Categories: immunology

Keywords: antigen presentation; cross-presentation; differentiation; Id2; priming; transcription factors

*Corresponding author. Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia. Tel.: +61 3 9345 2544; Fax: +61 3 9347 0852; E-mail: belz@wehi.edu.au

Received: 24 February 2011; accepted: 28 April 2011; published online: 17 May 2011

Introduction

CD11c $^+$ dendritic cells (DCs) are essential in presenting antigen to initiate T-cell responses. They have critical roles in immunity because of their ability to recognize invading pathogens and mobilize immune cells to combat them. DCs can be categorized into a number of different subsets that largely reflect the pattern of expression of cell surface molecules and functional specializations (Geissmann *et al*, 2010; Steinman and Idoyaga, 2010).

One major division of DCs is conventional DCs (cDCs) and plasmacytoid DCs (pDCs). In murine spleen, cDCs can be further divided into CD8 α^+ DCs, CD4 $^+$ DCs and CD8 α^- CD4 $^-$ (termed double-negative, DN) DCs. DCs enter the spleen and lymph nodes (LNs) through the blood as either mature pDCs or immature precursors of cDCs known as pro-DCs (reviewed in Liu and Nussenzweig (2010)). LNs contain multiple populations of DCs which include CD8 α^+ DCs and CD8 α^- DCs, together with DCs that migrate from the peripheral tissues (tissue-derived DCs). CD8 α^+ DCs contribute significantly to CD8 $^+$ T-cell activation *via* presentation of exogenous (den Haan and Bevan, 2002) or pathogen-derived antigens (Allan *et al*, 2003; Belz *et al*, 2004) while CD8 α^- DCs preferentially drive the activation of CD4 $^+$ T cells (Allenspach *et al*, 2008; Mount *et al*, 2008). Tissue-derived DCs differ depending on the type of peripheral tissues they drain. Langerhans cells (LCs) and the dermal DCs are found in skin while migratory tissue-derived CD103 $^+$ DCs originate from cutaneous and mucosal tissues such as the lamina propria of respiratory and gastrointestinal tracts (reviewed in Geissmann *et al* (2010)). The latter two DC subsets have a critical role in transporting antigens from body surfaces to LNs such that DCs resident in the LN can gain access to antigens (Liu and Nussenzweig, 2010).

Although a number of different DC subsets have been described, understanding how diverse DC subsets develop from a common progenitor is limited. Several factors have been identified as highly expressed in cDCs. These include inhibitor of DNA binding (Id)-2, interferon regulatory protein (Irf)-2 (Honda *et al*, 2004; Ichikawa *et al*, 2004), Irf-4 (Suzuki *et al*, 2004) and Irf-8 (Schiavoni *et al*, 2002, 2004; Tamura *et al*, 2005), PU.1 (Carotta *et al*, 2010), Ikaros, Gfi-1 (Rathinam *et al*, 2005), Batf3 (Hildner *et al*, 2008) and signal transducer and activator of transcription (Stat)-3 and Stat-5 (Wu and Liu, 2007; Merad and Manz, 2009).

Id2, a member of the helix-loop-helix (HLH) transcription factor family, is upregulated during DC development and is required for the development of CD8 α^+ DCs and LCs (Hacker *et al*, 2003). Id proteins act by antagonizing the DNA binding of activating E proteins and Id2 has been postulated to

repress pDC development by suppressing HEB and E2A as overexpression of these factors in haematopoietic progenitors led to enhanced pDC development (Schiavoni *et al*, 2002; Tamura *et al*, 2005). More recently, it was shown that a third HLH protein, E2-2, specifically regulates generation and maintenance of pDCs (Cisse *et al*, 2008). Irf proteins have broad effects in DC development. Loss of either Irf-2 or Irf-4 results in defects in the development of CD8 α ⁻ DCs while the absence of Irf-4 also disrupts pDC development in the spleen. In contrast, Irf-8 (also known as ICSBP) is required for CD8 α ⁺ DCs and pDC development (Schiavoni *et al*, 2002; Tamura *et al*, 2005). Similar to the impact of Irf-8 deficiency, inactivation of the Jun dimerization protein p21SNFT, *Batf3*, has also been reported to result in the loss of CD8 α ⁺ and tissue-derived CD103⁺ DCs, but does not impair pDC development (Hildner *et al*, 2008; Edelson *et al*, 2010).

CD103⁺ DCs found in peripheral LNs and lamina propria represent a heterogeneous group of cells in which those cells that express CD11b in the lamina propria do not appear to depend on Id2, Irf-8 or *Batf3* for development (Ginhoux *et al*, 2009; Edelson *et al*, 2010). The analysis of compound knock-out mice has led to a model in which conventional CD8 α ⁺ DCs and CD103⁺ DCs are thought to be developmentally related and possess similar functional and localization characteristics as both DC subsets are absent in mice lacking Id2, Irf-8 or *Batf3* (Hildner *et al*, 2008; Ginhoux *et al*, 2009; Edelson *et al*, 2010). Such models, however, are unable to discriminate between the stepwise requirement for each of these transcription factors for differentiation nor their impact on modulating survival of DC subsets once DC precursors have developed.

While much effort has focussed on the murine DC subsets, it is now becoming clear that many aspects of the human and mouse DC systems are closely aligned; and thus, murine models are likely to be highly informative in understanding human disease influenced by DC behaviour. DC subsets in the human blood can be distinguished by their expression of the surface molecules BDCA-1 (CD1c), BDCA-2 (CD303) and BDCA-3 (CD141) (Dzionek *et al*, 2000). BDCA-1⁺ cells represent a population of myeloid DCs; BDCA-2 marks pDCs, while BDCA-3 identifies the human counterpart of murine CD8 α ⁺ DCs which both share the high capacity to capture exogenous antigens for cross-presentation and the expression of chemokine receptor XCR1 (Bachem *et al*, 2010; Crozat *et al*, 2010; Jongbloed *et al*, 2010; Poulin *et al*, 2010). The interplay between these different DC subsets is of considerable interest as detailed understanding of their generation and responses offers opportunities for exploiting them as targets for vaccines and therapeutic interventions in cancer, autoimmunity and infection (Palucka *et al*, 2010). However, despite this significant progress, recovering sufficient human DC of the various subsets for molecular and transcriptional profiling remains challenging.

To understand how the complex network of DC lineages is generated in a model system, we engineered an Id2-GFP mouse reporter strain that enabled us to track endogenous Id2 expression on a single cell level during DC differentiation. As Id proteins are concentration-dependent antagonists of E protein activity, we reasoned that Id2 expression would be tightly regulated in DCs. Indeed, this was the case as cDC subsets expressed a wide range of Id2-GFP with the highest expression in CD8 α ⁺ and CD103⁺ DC lineages

in vivo. The equivalent DCs could also be identified in Flt3L-stimulated bone marrow cultures by correlating Id2 expression with surface expression of CD103 on DCs. By analysing Id2-GFP expression in the absence of *Irf-8* and *Batf3*, we were able to delineate that *Irf-8* is required for generation of both cDCs and pDCs, while in the absence of *Batf3* Id2-GFP⁺Sirp- α ⁻ (CD8 equivalent) DCs develop but CD103⁺ DCs do not. Furthermore, GM-CSF is a potent stimulator of CD103 expression *in vitro*, even in the absence of *Batf3*; however, GM-CSF could not rescue cross-presenting potential from the same mice. Thus, the ability to map Id2-GFP expression in developing murine DC subsets has wide application in understanding the precise molecular regulation of DC differentiation.

Results

To define the expression of Id2 and its role in different haematopoietic lineages, we generated a reporter allele by inserting an internal ribosome entry site (IRES)-GFP cassette into the 3' untranslated region of the *Id2* gene (Figure 1A). The targeted reporter allele, *Id2*^{gfp}, resulted in the transcription of a bicistronic mRNA that produced wild-type Id2 protein and GFP. This targeting strategy predicted that the IRES-GFP cassette would not affect the upstream *Id2* mRNA transcript. To confirm this, homozygous *Id2*^{gfp/gfp} mice were generated (Figure 1B). *Id2*^{gfp/gfp} mice were indistinguishable in survival, haematopoietic cellularity and lineage composition from C57BL/6 controls (NK cells: C57BL/6, $2.3 \times 10^5 \pm 6.7 \times 10^4$ /spleen; *Id2*^{gfp/+}, $1.94 \times 10^5 \pm 4.2 \times 10^4$ /spleen; *Id2*^{gfp/gfp}, $1.94 \times 10^5 \pm 1.9 \times 10^4$ /spleen; total DCs: C57BL/6, $2.1 \times 10^6 \pm 6.4 \times 10^4$ /spleen; *Id2*^{gfp/+}, $1.9 \times 10^6 \pm 8.3 \times 10^4$ /spleen; *Id2*^{gfp/gfp}, $2.1 \times 10^6 \pm 5.8 \times 10^4$ /spleen; and data not shown). As predicted, Id2-GFP was abundantly expressed in NK cells and silenced in B cells (Figure 1C). Moreover, the expression of GFP correlated exactly with *Id2* transcription in a variety of different haematopoietic lineages (Figure 1D).

Id2 expression in DCs *in vivo*

Next, we investigated Id2-GFP in DCs *in vivo* to determine if the level of expression identified individual DC subsets. To track the expression of Id2 in cDCs and pDCs *in vivo*, we isolated DCs from thymus, spleen and peripheral and mesenteric LNs of *Id2*^{gfp/gfp} mice (Figure 2A–E). This approach allowed the delineation of several populations of DCs not previously thought to express Id2 and showed that DCs isolated from different tissues expressed distinct amounts of Id2 (Figure 2A). Thymic DCs were divided into four populations with discrete fractions of both CD8 α ⁺Sirp- α ⁻ and Sirp- α ⁺ DCs expressing Id2-GFP (Figure 2B). pDCs, which were identified by their intermediate expression of CD11c and high expression of CD45RA, were uniformly very low for Id2-GFP (Supplementary Figure S1). In spleen and LN, all cDCs (defined as CD11c^{high}) expressed Id2-GFP but varied in the level of expression among the different DC subsets (Figure 2C–E). Unexpectedly, CD4⁺ DCs in spleen and DN DCs in spleen and LN also expressed Id2-GFP (Figure 2C). Id2-GFP fluorescence in cells of the monocyte/macrophage lineages was at a level that was similar to DN DCs and dermal DCs, respectively (Figure 2C, D and F).




Figure 1 Generation and validation of *Id2*^{GFP} reporter mouse strains. (A) The genomic locus of *Id2*. Exons are represented by boxes; introns are represented as black lines; coding regions are shaded yellow; non-translated regions are in white; arrows indicate the direction of translation. The alleles derived from the integration of the targeting vector and subsequent manipulations are shown. pA, polyadenylation signal sequence; circles, *frt* sites; triangles, *loxP* sites. The *Id2*-GFP reporter line was derived from an embryonic stem cell (ES) clone that lacked the 5' *LoxP* site and was identified by PCR. The position and direction of the genotyping primers (*a-c*) and the *SacI* and *XbaI* sites used for Southern blotting are indicated. (B) Southern blot analysis of ES cell *SacI*-digested DNA showing the wild-type (12.6 kb) and targeted (8.9 kb) alleles (left panel). PCR genotyping of tail DNA using the primer set *a/b/c* showing the correct amplification of the wild-type (688 bp) and *Id2*^{GFP} (959 bp) alleles (right panel). (C) *Id2*-GFP expression in B220⁺IgM⁺ B cells derived from peripheral LNs and splenic NK1.1⁺CD49b⁺ NK cells from naive wild-type (black line) and *Id2*^{GFP/GFP} mice. (D) Quantitative PCR analysis for the indicated transcripts of live (PI⁻) mixed populations of cells from spleen, thymus and bone marrow purified on the basis of their expression of *Id2*-GFP. Data are the mean \pm s.e.m. of two experiments.

Id2 expression in haematopoietic progenitors

Given that all cDC subsets expressed some level of *Id2*-GFP, we wished to examine whether *Id2* was induced during DC differentiation or alternately might be constitutively expressed in precursor DCs and down modulated as populations matured. *Id2*-GFP expression was negligible in lineage-negative sca^{high}c-kit^{high} (LSK) cells (including the Flt3⁺ lymphoid primed multipotent progenitor, LMPP), common lymphoid progenitors and common DC progenitors (CDPs, also known as pro-DCs) (Figure 3A and B). Similarly, BM and splenic pre-cDCs had showed little upregulation of *Id2* (Figure 3C) and analysis of CD11c⁺ bone marrow DCs revealed that a

large fraction of cells were low or negative for *Id2*-GFP (Figure 3D) demonstrating that activation of the *Id2* gene occurred relatively late in the differentiation of DCs. Thus, *Id2* expression is induced in precursors that have been committed to the cDC pathway.

Id2 expression in DCs *in vitro*

The different amounts of *Id2*-GFP observed in different DC subsets *in vivo* led us to propose that distinct levels of *Id2* expression could be used to define DC subsets and this hierarchy may also be maintained *in vitro*. If so, *Id2*-GFP mapping of DC subsets *in vitro* would enable the recovery of DC subsets in




Figure 2 Multiple DC subsets express Id2 *in vivo*. Id2^{8fp/8fp} (green line) and wild-type (black line) cells were analysed by flow cytometry for GFP expression in different DC and myeloid populations. The different cell types were defined as described in Materials and methods. (A) Total DC (CD11c⁺) populations from thymus, spleen, peripheral LN and mesenteric LNs; (B) thymic DC populations; (C) splenic DC populations; (D) peripheral (pooled DCs from inguinal, brachial, axillary, superficial cervical LNs) and (E) mesenteric LN DCs; and (F) monocyte and macrophage (from peritoneal lavage) lineages. All plots are gated on CD11c⁺ cells and markers as indicated in the dot plots (left panels). In (D), the fluorescence intensity of Langerhans cells has been shown in red for comparison. Mean fluorescence intensity (MFI) is shown for GFP expression for each gated population. Data are representative of at least two to three independent experiments.




Figure 3 Expression of Id2 in lymphoid progenitors. (A) Bone marrow progenitor cells were analysed by depletion of lineage expressing cells then stained for sca-1, c-kit, M-CSFR and Flt3 and analysed by flow cytometry for lin⁻sca-1⁺c-kit⁺ (LSK) cells, lymphoid primed multipotent progenitors (LMPPs, defined as LSKFlt3^{high}), common lymphoid progenitors (CLPs) and (B) common DC progenitor (CDPs) as indicated. (C) Bone marrow and splenic DC progenitors were analysed by depletion of lineage expressing cells (CD19, NK1.1, CD3 and Ter119) then stained for CD11c, Flt3, MHC II and Sirp- α and analysed for the pre-cDC population by flow cytometry (Liu and Nussenzweig, 2010). Profiles show the gating strategy in which CD11c⁺MHC II⁻ cells (region 1, R1) were then selected for expression of Flt3 and Sirp- α (region 2, R2). (D) CD11c⁺ cells were isolated from bone marrow by density gradient centrifugation. Gated populations from *Id2*^{GF1p/GFP} (green line) and wild-type (black line) mice were then assessed for GFP fluorescence. Data are representative of at least two experiments.

sufficient numbers for the detailed dissection of the functional and molecular aspects of DC development. It should be noted that although the surface molecule CD8 α is expressed on DCs isolated directly *ex vivo*, this marker is not expressed on *in vitro*-derived CD8 α -equivalent DCs. These cells have been previously identified by their lack of expression of Sirp- α , and as shown below, intermediate expression of CD45RA. As observed *in vivo*, DCs generated *in vitro* expressed graded levels of

Id2-GFP allowing us to discriminate six distinct DC populations (Figure 4A–C). These could be divided into the Id2-GFP negative populations that also lack CD103 expression (1) CD45RA⁻ DCs; (2) CD45RA^{int} DCs that expressed the pDC markers Bst-2 and Siglec-H (Figure 4A, right panels); (3) CD45RA^{high} (analogous to the previously described mature pDC); and the Id2-GFP expressing populations; (4) CD45RA⁻ DCs; and (5) CD45RA^{int} (Figure 4B). Further dissection of the Id2-GFP⁺ cDC populations

revealed the presence of CD45RA⁻CD103⁺ DCs that expressed the highest amounts of Id2-GFP (population 6, Supplementary Table S1). Tissue-derived CD103⁺ cDCs have not been previously identified *in vitro* but this staining was specific as it was not detected in similar cultures derived from *Itgae*^{-/-} (CD103-deficient) mice (Supplementary Figure S2). This analysis also showed that the Id2-GFP⁺CD45RA⁻ population (pop. 4) of DCs was Sirp- α ⁺ while the Id2-GFP⁺CD45RA^{int} population (pop. 5) was predominantly Sirp- α ⁻ and these populations expressed distinct levels of CD24 consistent with the previously described *in vitro* phenotype of CD8 α ⁻ DCs and CD8 α ⁺ DCs (Figure 4C; Naik *et al*, 2005).

Differentiation of *in vitro* generated DC subsets

To determine the relationship between different populations of DCs observed *in vitro*, DC subsets from day 5 cultures were purified into the six fractions described in Figure 4 and re-cultured in Flt3L-conditioned medium for further 3 days (Supplementary Figure S3). We hypothesized that Id2-GFP⁻CD45RA⁻ DCs (pop. 1) contained multipotent DC precursors. Concordant with this notion, this subset gave rise to all identified *in vitro* subsets of DCs. Id2-GFP⁻CD45RA^{hi} (pop. 3) generated only pDCs while Id2-GFP⁻CD45RA^{int} DCs (pop. 2) predominantly gave rise to Id2-GFP⁻CD45RA^{hi} cells, suggesting that they contain the major immature population of pDCs. CD103⁻Id2-GFP⁺CD45RA⁻Sirp- α ⁺ DCs (pop. 4) maintained their phenotype while CD103⁻Id2-GFP⁺CD45RA^{int}Sirp- α ⁻ DCs (pop. 5) generated Sirp- α ⁻ DCs that expressed varying levels of CD103 and CD103⁻Sirp- α ⁺ DCs. In contrast, CD103⁺ DCs (pop. 6) almost exclusively gave rise to CD103⁺ DCs, suggesting that these cells are terminally differentiated. Thus, it appears that some *in vitro* subsets represent end-state DC populations (e.g., mature pDCs and CD103⁺ DCs) while other subsets retain differentiation potential. Similarly, Id2-GFP⁻CD45RA^{int} DCs appear to be immature pDCs. This was further supported by the failure of Id2-GFP⁻CD45RA^{int} DCs to upregulate CD80 and MHC class II in response to TLR ligands such as LPS or poly I:C and the induction of these activation markers following stimulation with CpG motifs (Supplementary Figure S4). Thus, the *in vitro* culture contains a combination of early developing and differentiated DCs that may represent the counterparts of blood-derived lymphoid tissue-resident and tissue-derived DCs.

Characteristics of CD103⁺ DCs *in vitro*

One property that varies extensively among DC subsets is the ability to take up exogenous antigens and divert these antigens into the MHC class I pathway—a process known as cross-presentation and is thought to be of major importance for the recognition of viral or bacterial antigens when DCs are not directly infected (Carbone and Bevan, 1990). In mice, CD8 α ⁺ DCs, and more recently CD103⁺ DCs, have been identified as the major cross-presenting populations *in vivo*. Similarly, the CD8 α ⁺ DC counterpart in humans, BDCA-3 DCs, also exhibit more efficient cross-presenting ability *in vitro* (Bachem *et al*, 2010; Crozat *et al*, 2010; Jongbloed *et al*, 2010; Poulin *et al*, 2010). Despite this, in model systems such as Flt3L bone marrow cultures, the identification of the DC subset(s) that can efficiently and constitutively cross-present exogenous antigens has been more elusive and has limited detailed molecular studies of this cell type.


Given our identification of CD103⁺ DCs *in vitro*, we tested the ability of CD103⁻Id2-GFP⁺CD45RA⁻Sirp- α ⁺ (pop. 4), CD103⁻Id2-GFP⁺CD45RA^{int}Sirp- α ⁻ (pop. 5; CD8 α ⁺ DC equivalents) and CD103⁺Id2-GFP⁺ DCs (pop. 6) for their capacity to cross-present cell-associated antigens. Initially, we chose to analyse DCs isolated from day 5 cultures as population 5 reaches its maximal prevalence at this time point. DCs were purified and then co-cultured with OVA-coated bm-1 splenocytes (which cannot present antigen on H-2K^b) and analysed for their capacity to induce proliferation of CFSE-labelled OVA-specific CD8⁺ T cells (OT-I cells). The presentation of OVA to CFSE-labelled OVA-specific CD4⁺ T cells (OT-II cells) was used as a control to determine that all populations of DCs could present OVA antigens. Strikingly, strong cross-presentation to CD8⁺ T cells was only elicited from CD103⁺Id2-GFP⁺ stimulators but not from other populations of DCs (Figure 4D). In contrast, all DC populations were able to present exogenous OVA antigen to CD4⁺ T cells. Similar analysis of DC populations at day 8 of culture showed that CD103⁺Id2-GFP⁺CD45RA⁻ DCs remained the only *in vitro* DC subset capable of cross-presenting cell-associated antigen (Supplementary Figure S5). However, the efficiency of presentation at this time point was reduced (data not shown). Although CD103 was a marker of this discrete subset of DCs, CD103 expression itself was not required for cross-presentation of cell-associated OVA *in vivo* (Figure 4E) and indeed appeared to be strongly downregulated on activation of DCs (Figure 4F). Thus, unexpectedly, the major *in vitro* DC that could constitutively cross-present cell-associated antigens were not Sirp- α ⁻ DCs (equivalent to CD8 α ⁺ DCs) but CD103⁺ DCs.

Id2-GFP reveals overlapping but non-redundant roles of Irf-8 and Batf3 during CD8 α ⁺ DC and CD103⁺ DC differentiation

Id2, Irf-8 and Batf3 are transcription factors implicated in the development of CD103⁺ and CD8 α ⁺ DCs (Schiavoni *et al*, 2004; Hildner *et al*, 2008; Ginhoux *et al*, 2009; Edelson *et al*, 2010). However, precisely where in DC differentiation these transcription factors determine the fate decision between CD103⁺ and CD8 α ⁺ DCs is unknown. First, we analysed the expression pattern of the transcription factors Id2, Irf-8 and Batf3 in the different DC populations *in vitro* and *in vivo* (Figure 5). While this demonstrated differential expression of the transcription factors among different DC subsets, the *in vitro* (Id2-GFP⁺CD45RA⁺) and *in vivo* CD8 α ⁺ and CD103⁺ DCs concordantly expressed high levels of *Id2*, *Irf-8* and *Batf3*. In an attempt to delineate whether Irf-8 or Batf3 differentially affect particular DC subsets during development, we crossed the *Id2*^{gfp/gfp} mice with *Batf3*^{-/-} or *Irf-8*^{-/-} mice. At days 5 and 8, Flt3L-stimulated bone marrow cultures were analysed. As shown earlier (Figure 4) Id2-GFP marked the differentiating cDC populations, but not pDCs. Removal of Irf-8 resulted in loss of both the Id2-GFP⁺CD45RA^{int}Sirp- α ⁻ DCs that give rise to Id2-GFP⁺Sirp- α ⁻ (CD8 α ⁺ equivalent) DCs and CD103⁺Id2-GFP⁺ DCs, whereas *Batf3* was only required for CD103⁺Id2-GFP⁺ DCs (Figure 6A). While, *Batf3*^{-/-} cultures generated normal numbers of Id2-GFP⁺CD45RA^{int}Sirp- α ⁻ DCs at day 5, a significant reduction in the frequency of these cells was observed at day 8 (Figure 6B). These findings suggest that Id2-GFP⁺CD45RA^{int}Sirp- α ⁻ (CD8 α equivalent) DCs are gene-

rated in the absence of *Batf3* and that this transcription factor may have a critical role in the survival and/or maintenance of these DCs. In line with this, *in vivo* analysis of the *Id2^{gfp/gfp} × Batf3^{-/-}* mice revealed a population of DCs that expressed *CD8α* at low levels and *Id2-GFP* expression similar to those found in *Id2^{gfp/gfp}* mice (Supplementary

Figure S6). To further explore the mechanism by which *Batf3* influences cDC development, we measured proliferation (Figure 6C) and cell death (Figure 6D and E) at 5 and 8 days of DC culture. These data showed no difference in the level of incorporation of BrdU between *Id2^{gfp/gfp}* and *Id2^{gfp/gfp} × Batf3^{-/-}* DCs on day 5 or 8 of culture (Figure 6C).



Intriguingly, most of the proliferative potential at this point lay in the $Id2\text{-GFP}^+ CD45RA^{int} Sirp\text{-}\alpha^-$ population. In the absence of *Batf3*, the level of death in the $Id2\text{-GFP}^+ CD45RA^{int} Sirp\text{-}\alpha^-$ population was similar to wild-type controls at day 5 of culture; however by day 8, the proportion of cells expressing Annexin V

increased ~ 2 -fold (Figure 6D). This increase appeared to be specific as other DC subsets analysed in the same experiments showed comparable levels of Annexin V staining between $Id2^{gfp/gfp}$ and $Id2^{gfp/gfp} \times Batf3^{-/-}$ DCs.

GM-CSF induces CD103 expression in *Batf3*-deficient DCs but does not restore cross-presentation of cell-associated antigens

Recently, GM-CSF has been implicated in the development of a population of $CD103^+$ DCs (King *et al*, 2010). To test whether GM-CSF could overcome the failure to develop $CD103^+$ DCs in $Batf3^{-/-}$ Flt3L-stimulated cultures, GM-CSF was added to DC cultures 2 days before analysis (Figure 7A). This treatment resulted in an increase in the frequency of $CD103^+ Id2\text{-GFP}^+$ DCs in $Id2^{gfp/gfp}$ cultures and the emergence of $CD103^+ Id2\text{-GFP}^+$ DCs from $Id2^{gfp/gfp} \times Batf3^{-/-}$ bone marrow. Next, we tested whether GM-CSF treatment could induce cross-presenting capacity in $Batf3^{-/-}$ DCs (Figure 7B). $CD103^+ Id2\text{-GFP}^+$ DCs isolated from $Id2^{gfp/gfp}$ cultures exposed to GM-CSF resulted in a two-fold increase in the capacity to amplify OVA-specific $CD8^+$ T cells. In contrast, $CD103^+ Id2\text{-GFP}^+$ DCs isolated from $Id2^{gfp/gfp} \times Batf3^{-/-}$ cultures did not gain the capacity to cross-present cell-associated OVA. Similarly, $CD103^- Id2\text{-GFP}^+ CD45RA^{int} Sirp\text{-}\alpha^-$ DCs from exposed to GM-CSF did not gain cross-presenting function regardless of their *Batf3* genotype (Figure 7B). Thus, GM-CSF appears to optimize cross-presenting capacity in $CD103^+ Id2\text{-GFP}^+$ DCs but does not overcome defects in cross-presentation in the absence of *Batf3* despite the rescue of expression of *CD103*.

GM-CSF does not amplify $CD103^+$ or $Sirp\text{-}\alpha^-$ DCs in the absence of *Irf-8*

Loss of *Irf-8* appears to almost completely block $CD103^+ Id2\text{-GFP}^+$ and $CD103^- Id2\text{-GFP}^+ CD45RA^{int} Sirp\text{-}\alpha^-$ DC development (Figure 5; Aliberti *et al*, 2003; Tailor *et al*, 2008). To determine whether this block could be overcome by extrinsic signals provided by GM-CSF, $Id2^{gfp/gfp} \times Irf-8^{-/-}$ bone marrow was co-cultured with Flt3L \pm GM-CSF as described above (Figure 8A). These culture conditions did not induce the generation of either DC subset but $Sirp\text{-}\alpha^+$ DCs (Figure 8A; $Id2\text{-GFP}^+ CD45RA^-$ DCs) were generated at a similar frequency to $Id2^{gfp/gfp}$ cultures. Thus, *Irf-8* appears to be a critical regulator $CD103^+$ and $CD8\alpha$ lineages but other $Id2\text{-GFP}^+$ cDCs can be induced in response to exogenous growth factors in its absence.




Figure 5 Quantitative RT-PCR analysis of the transcription factors *Id2*, *Irf-8* and *Batf3* in purified *in vitro*-derived and *in vivo* DC subsets. $CD11c^+$ $CD45RA^+$ $Id2\text{-GFP}^-$ cells expressed markers of pDCs. Histograms show expression of *Bst2* (upper right panel) and *Siglec-H* (lower right panel) of total $CD45RA^{int}$ cells (grey shading), $CD45RA^{int} Id2\text{-GFP}^-$ immature pDCs (black line). The expression of markers for $CD103^- CD45RA^{high}$ (mature) pDC is indicated in red. (B) Populations 4, 5 and 6 could be discriminated based on their expression of *Sirp- α* or *CD103*. Profiles are representative of at least 10 independent experiments with similar results. (C) $Id2\text{-GFP}$ DC subsets express distinct levels of *Sirp- α* and *CD24*. (D) *In vitro* generated $Id2^{gfp/gfp}$ DCs were flow cytometrically sorted 5 days after initiation of cell culture according to their expression of *CD103*, *CD45RA*, *Sirp- α* and *Id2-GFP* and analysed for their ability to cross-present cell-associated OVA to CFSE-labelled OVA-specific $CD8^+$ T cells (upper panels). The ability of these subsets of present exogenous antigen to CFSE-labelled OVA-specific $CD4^+$ T cells was evaluated as a control (lower panels). Data are representative of four independent experiments. T-cell proliferation was analysed in 1–3 replicates for each DC subset/responder population for each experiment. (E) $Ly5.1^+$ CFSE-labelled $CD8^+$ OVA-specific T cells were adoptively transferred into $H\text{-}2K^{bm-1}$, B6 or *Itgae*^{-/-} mice 1 day before transfer of 2×10^7 OVA-coated $H\text{-}2^{bm-1}$ splenocytes. Proliferation of $Ly5.1^+ V\alpha 2^+ CD8^+$ T cells in spleen was analysed by flow cytometry after 60 h. Data are representative of two independent experiments with seven individuals analysed in each group. (F) The expression level of surface *CD103* was monitored by flow cytometry 18 h after exposure to TLR ligands LPS or CpG. Data are representative of at least five independent experiments and show MFI expression levels.

Figure 4 *In vitro* cross-presentation in Flt3L-stimulated cultures is limited to $CD103$ -expressing $Id2\text{-GFP}^{high}$ DCs. (A–C) Flt3L-derived DCs from $Id2^{gfp/gfp}$ BM were analysed on day 5 of culture. Six different DC populations were discriminated based on their expression of *CD11c*, *CD45RA* and *CD103*. Right panels: $CD11c^+$ $CD45RA^+$ $Id2\text{-GFP}^-$ cells expressed markers of pDCs. Histograms show expression of *Bst2* (upper right panel) and *Siglec-H* (lower right panel) of total $CD45RA^{int}$ cells (grey shading), $CD45RA^{int} Id2\text{-GFP}^-$ immature pDCs (black line). The expression of markers for $CD103^- CD45RA^{high}$ (mature) pDC is indicated in red. (B) Populations 4, 5 and 6 could be discriminated based on their expression of *Sirp- α* or *CD103*. Profiles are representative of at least 10 independent experiments with similar results. (C) $Id2\text{-GFP}$ DC subsets express distinct levels of *Sirp- α* and *CD24*. (D) *In vitro* generated $Id2^{gfp/gfp}$ DCs were flow cytometrically sorted 5 days after initiation of cell culture according to their expression of *CD103*, *CD45RA*, *Sirp- α* and *Id2-GFP* and analysed for their ability to cross-present cell-associated OVA to CFSE-labelled OVA-specific $CD8^+$ T cells (upper panels). The ability of these subsets of present exogenous antigen to CFSE-labelled OVA-specific $CD4^+$ T cells was evaluated as a control (lower panels). Data are representative of four independent experiments. T-cell proliferation was analysed in 1–3 replicates for each DC subset/responder population for each experiment. (E) $Ly5.1^+$ CFSE-labelled $CD8^+$ OVA-specific T cells were adoptively transferred into $H\text{-}2K^{bm-1}$, B6 or *Itgae*^{-/-} mice 1 day before transfer of 2×10^7 OVA-coated $H\text{-}2^{bm-1}$ splenocytes. Proliferation of $Ly5.1^+ V\alpha 2^+ CD8^+$ T cells in spleen was analysed by flow cytometry after 60 h. Data are representative of two independent experiments with seven individuals analysed in each group. (F) The expression level of surface *CD103* was monitored by flow cytometry 18 h after exposure to TLR ligands LPS or CpG. Data are representative of at least five independent experiments and show MFI expression levels.




Figure 6 *Id2*, *Irf-8* and *Batf3* regulate distinct DC subsets *in vitro*. (A) Flt3L-derived DCs from *Id2^{gfp/gfp}*, *Id2^{gfp/gfp} Irf-8^{-/-}* and *Id2^{gfp/gfp} Batf3^{-/-}* mice were analysed for the development of different DC subsets. Cells were stained for their expression of CD11c, CD45RA and CD103 at days 5 and 8 after initiation of cultures. Data show CD11c⁺ cells and are representative of at least three independent experiments. (B) Total number of CD11c⁺ and Id2-GFP⁺CD45RA^{int}CD103⁻ DCs generated per 1.5 × 10⁶ bone marrow input cells from *Id2^{gfp/gfp}* and *Id2^{gfp/gfp} Batf3^{-/-}* bone marrow at days 5 and 8 in the presence of 100 ng/ml Flt3L. Data show mean ± s.e.m. of six individual cultures for each strain at each time point. (C) Histograms (top panels) showing representative profiles of BrdU incorporation in *in vitro* generated Id2-GFP⁺CD45RA^{int}CD103⁻ DCs from *Id2^{gfp/gfp}* and *Id2^{gfp/gfp} Batf3^{-/-}* bone marrow on day 5 of culture. Bar graphs show BrdU incorporation for each DC subset. Data show the mean ± s.e.m. of cultures from bone marrow of 6–9 individual mice for each strain at days 5 and 8. (D, E) Analysis of Annexin V expression on DCs generated as in (C). Cells were stained for surface markers as indicated before staining for Annexin V expression and analysis by flow cytometry. (D) Graph shows expression on days 5 and 8 showing the mean ± s.e.m. of cultures from bone marrow of six individual mice pooled from two independent experiments for each strain at days 5 and 8. (E) Histograms show representative profiles of Annexin V staining on day 8 in total CD11c⁺ DCs, Id2-GFP⁺CD45RA^{int} and Id2-GFP⁺CD45RA⁻ DC subsets derived from *Id2^{gfp/gfp}* or *Id2^{gfp/gfp} Batf3^{-/-}* bone marrow. Statistical differences were determined using a one-tailed Student's *t*-test.






Figure 7 GM-CSF enhances expression of CD103 but does not restore cross-presenting function in the absence of Batf3. **(A)** Bone marrow from *Id2^{gfp/gfp}* and *Id2^{gfp/gfp} × Batf3^{-/-}* mice was cultured with Flt3L for 5 days. In some cases, GM-CSF was added 2 days before analysis of cultures for the development of different DC subsets. Profiles are gated on CD11c⁺CD19⁻NK1.1⁻CD3⁻ cells. **(B)** DCs of the indicated genotypes were generated *in vitro* in response to Flt3L or Flt3L and GM-CSF as described in **(A)**. DCs were flow cytometrically sorted 5 days after initiation of cell culture according to their expression of CD103, CD45RA, Sirp-α and Id2-GFP and analysed for their ability to cross-present cell-associated OVA to CFSE-labelled OVA-specific CD8⁺ T cells (left panels). The ability of these subsets of present exogenous antigen to CFSE-labelled OVA-specific CD4⁺ T cells was evaluated as a control (right panels). Data are representative of at least three independent experiments with similar results and show the mean ± s.d. (*n* = 6–10 per genotype).

Discussion

This study provides new insights into the transcriptional regulation of DC fate decisions and DC subset formation. Our data show that *Irf-8* is critical for the development of CD8α⁺ and CD103⁺ DCs and places *Id2* upstream of *Batf3* in regulating differentiation of each of these subsets, respectively (Figure 8B). In addition, the growth factor GM-CSF can

induce phenotypic expression of CD103 in DCs but does not induce cross-presenting capacity in these cells.

Despite the known importance of *Irf-8*, *Id2* and *Batf3* in DC development, there is little known about precisely how different transcription factors establish the identity of DC subsets *in vivo*. This is in part attributable to partial overlap between the functions of genes associated with DC differentiation. Furthermore, *in vitro* approaches that allow the



generation of sufficient numbers of DCs to study DC subset gene regulation or differentiation in detail have relatively low resolution. Engineering reporter capacity into a functional *Id2* gene has enabled us to begin to investigate *in vivo* and *in vitro* differentiation patterns of DC lineages. A recently developed *Id2^{del}*-GFP mouse has been used to trace lung epithelial cell development from progenitors (Rawlins *et al*, 2009) though this model has not been investigated for other cell types. Analysis of mRNA has provided some insight to the broader expression of *Id2* in DCs (Ginhoux *et al*, 2009); however, this approach lacks the single cell precision of the *Id2*-GFP reporter and precludes subsequent analysis of function in live cells. In addition, from our studies, crossing the *Id2^{GFP}* mice with strains deficient in various transcription factors has opened the capacity to identify the checkpoints in DC lineage development both *in vitro* and *in vivo* that have not been readily resolved using knockout models.

Here, we have shown that *Irf-8* and *Batf3* differentially regulate DC subset development (Figures 6 and 8B). *Batf3* is required for the generation of LN-derived DCs of the CD103⁺ and CD8 α ⁺ lineages (Hildner *et al*, 2008; Edelson *et al*, 2010). Although differing in cell surface phenotype, these two cell types *in vivo* are almost identical with CD103⁺ DCs being distinguished from LN CD8 α ⁺ DCs by their expression of *XCR1* and their enhanced capacity to cross-present exogenous antigens. *XCR1*, a chemokine receptor expressed on murine splenic CD8 α ⁺ DCs (Dorner *et al*, 2009) together with CD103⁺ DCs, appears also to define the CD11c⁺CD141⁺ human homologues of mouse CD8 α ⁺ DCs (Bachem *et al*, 2010; Crozat *et al*, 2010; Jongbloed *et al*, 2010; Poulin *et al*, 2010). The essential function of *Batf3* *in vitro* was restricted to the CD103⁺ DC subset with substantial reduction in *Sirp- α* ⁻ DCs (CD8 α ⁺ equivalents) observed late during culture. This is consistent with earlier observations of reduced *Sirp- α* ⁻ DCs following Flt3L culture (Hildner *et al*, 2008) but notably when we enumerated the *Sirp- α* ⁻ splenic precursor cells earlier in culture, they were not significantly impaired. This highlights a previously unrecognized role that transcription factors such as *Batf3* might have in maintaining DCs, specifically CD8 α ⁺ DCs, in the periphery. Interestingly, Flt3L, an important growth factor for DCs, is also required for peripheral DC proliferation (Waskow *et al*, 2008).

DCs are critical for the collection and processing of antigens for presentation to lymphocytes. Their role as sentinels guard-

ing different tissue environments in the body has led to the development of an intricate network of distinct DC subsets. The regulation of transcription factors that control the differentiation and survival of DCs is essential for DC development. Our work highlights that the developmental hierarchy of DCs is guided by combinatorial activity of transcription factors that drive specific DC subset formation. Intriguingly, transcription factors such as PU.1, and Ikaros appear to have essential roles for the development of virtually all DCs. Ikaros is required for the development of cDCs and pDCs in line with its essential function in normal development of early haematopoietic progenitors (Nichogiannopoulou *et al*, 1999). PU.1 is intrinsically required for the generation of all DC lineages from early progenitors and regulates the decision-making process through graded expression of Flt3 (Carotta *et al*, 2010). In contrast, *Id2*, *Batf3* and *Irf-8* have non-redundant subset-specific functions that result in the development of distinct DC lineages. *Irf-8* is essential for the development of both pDC and CD8 α ⁺ DC family members; *Id2* guides the subsequent development of cDCs, while *Batf3* is not required for the development of CD8 α ⁺ DCs, but is necessary for their survival and is essential for the development of CD103⁺ DCs (Figure 8B).

Recently, an unexpected role for GM-CSF in promoting differentiation of CD103⁺ cells was uncovered (King *et al*, 2010). GM-CSF is a growth factor that promotes differentiation of myeloid cells but also influences the homeostatic development of DCs (Hamilton and Anderson, 2004; Kingston *et al*, 2009). We found that GM-CSF in combination with Flt3L stimulation could induce the expression of CD103 on the surface of DCs. However, while this enhanced the efficiency of cross-presentation in CD103⁺ DC, it failed to induce cross-presenting capacity in *Id2*-GFP⁺*Sirp- α* ⁻ DCs from wild-type mice or DCs derived from *Batf3^{-/-}* bone marrow. This suggests that extrinsic factors such as GM-CSF may modulate DC differentiation and phenotype during development and enhance antigen presentation to promote T-cell responses (King *et al*, 2010). Furthermore, it indicates that while *Batf3^{-/-}* mice do possess CD8 α ⁺ DCs, the major defect may lie in their intrinsically impaired ability to cross-present antigens combined with the failure of specific DC subsets to differentiate and survive.

In conclusion, we describe an approach that allowed the prospective identification of individual DC populations using

Figure 8 (A) GM-CSF does not induce CD103⁺ or *Sirp- α* ⁻ DCs but enhances *Id2*-GFP⁺*Sirp- α* ⁺ DC development in the absence of *Irf-8*. (A) Bone marrow from *Id2^{GFP/GFP}* and *Id2^{GFP/GFP} × Irf-8^{-/-}* mice was cultured with Flt3L for 8 days. In some cases, GM-CSF was added 2 days before analysis of cultures for their expression of CD103, CD45RA and *Id2*-GFP. Dot profiles are gated on CD11c⁺NK1.1⁻CD19⁻CD3 ϵ ⁻PI⁻ cells. (B) The expression of *Sirp- α* on *Id2*-GFP⁺ cells (indicated by the blue box, panel (A)) is shown. The percent of *Sirp- α* ⁺ and *Sirp- α* ⁻ cells for CD11c⁺*Id2*-GFP⁺ cells is shown on each plot. Data are representative of at least three independent experiments with similar results and show the mean \pm s.d. ($n = 6-8$ per genotype). (B) Model of differentiation of DCs and the requirement for *Id2*, *Irf-8* and *Batf3* in this process. Common DC and pre-DCs do not express *Id2* and can be activated by Flt3L stimulation. *Irf-8* is required for the generation of pDCs, CD8 α ⁺ and CD103⁺ DCs, but not DN DCs which can be induced to differentiate in the absence of both *Id2* or *Irf-8* when exposed to cytokines such as GM-CSF. *Id2* is induced in differentiating cDCs and is required for the generation of CD8 α ⁺ and CD103⁺ DCs, but not pDCs, found in spleen and peripheral LNs. *Batf3* is essential for the generation of CD103⁺ DCs but is dispensable for the development of precursor CD8 α ⁺ DCs which depend on *Batf3* for their maintenance and full differentiation into mature cells in spleen and peripheral tissues. Precursor cells—CDP and Pre-DCs—are defined as *lin⁻ckit^{int}Flt3⁺M-CSF⁺* and *lin⁻CD11c^{int}Flt3⁺Sirp- α ⁺MHC II⁻*, respectively, as previously defined (Naik *et al*, 2006; Liu *et al*, 2009). These precursor populations do not express *Id2* suggesting that a transitional cDC stage (transitional pre-DC) occurs in which *Id2* expression is switched on but DCs have not yet adopted their mature phenotypes. Mature DCs have been defined as described in Supplementary Table S1. Data describing the role of *Id2* are derived from unpublished experiments in which *Id2* has been specifically ablated in CD11c-expressing cells using Cre-mediated deletion (JTJ and GTB.; Ginhoux *et al*, 2009). The presence of precursor CD8 α ⁺, but not mature, CD8 α ⁺ DCs are evident by their expression of the CD11c⁺*Id2*-GFP⁺CD45RA^{int}*Sirp- α* ⁻ phenotype in the absence of *Batf3*. The red lines represent where loss of a transcription factor blocks further DC development.

the Id2-GFP reporter mouse but which now can be more broadly applied to other mouse strains. Translation of these analyses to our highly defined *in vitro* system now enables us to investigate the collaborative transcription program of DC differentiation and the plasticity of DC subsets responding to extrinsic signals such as cytokines and inflammatory stimuli. Furthermore, it is now feasible to generate murine DC subsets, which have equivalent human counterparts, in sufficient numbers to permit detailed molecular analysis of their behaviour at steady state and in response to pathogen stimuli. This will shed light on the role of DC network composed of multiple DC subsets with distinct functions required to maintain tolerance or drive immunity.

Materials and methods

Construction of *Id2^{gfp/gfp}* reporter mice

The *Id2* targeting construct used the pKW11 vector consisting of a splice acceptor, stop codons in all reading frames, an IRES, *eGFP* cDNA, an SV40 polyadenylation signal and a *PGK-Neo^r* gene. Genomic DNA containing *LoxP* flanked *Id2* exons 1–2, containing the entire *Id2* coding region was cloned in front of the pKW11 insert. Homology arms of 5794 bp (5') and 6161 bp (3') were amplified from an *Id2*-containing BAC and cloned into the final targeting vector. The linear targeting vector was introduced into the *Id2* locus by homologous recombination in C57BL/6 ES cells. The targeting vector was inserted so that the 5' *LoxP* sites were introduced into the 5' untranslated region of *Id2* at position –71 bp compared with the *Id2* start codon. Neomycin-resistant clones were screened by Southern hybridization using 5' (digested with *Xba*I, giving wild type 8819 kb and *Id2^{fl-sfp}* 7255 kb) and 3' (digested with *Sac*I, giving wild type 12 578 kb and *Id2^{fl-sfp}* 8916 kb) probes. Targeted ES cell clones were injected into BALB/c blastocysts to obtain chimeric founders. Germ-line transmission was achieved with two clones, resulting in the generation of two lines. Founders for the reporter lines lacked the 5' *LoxP* site and were designated as *Id2*-reporter (*Id2^{gfp/gfp}*). PCR genotyping was performed using the primer combination: *a*: 5'-TGCCTATGTGGTAAGTCAAGCGG-3', *b*: 5'-GCCG AATTCATTTAATCACCCA-3', *c*: 5'-CTCCAAGCTCAAGGAAGTGG-3'. Primer combination *a/b/c* gave PCR fragments of 688 bp (*a/c* wild type) and 959 bp (*a/b Id2^{gfp}*).

Mice

Id2^{gfp/gfp}, *Id2^{gfp/+}*, C57BL/6, B6.CH-2^{bm-1} (bm1), OT-I (Hogquist *et al*, 1994), OT-II (Barnden *et al*, 1998), *Batf3^{-/-}* (Hildner *et al*, 2008), *Irf8^{-/-}* (Holtschke *et al*, 1996) and *Itgae^{-/-}* (Schon *et al*, 2000) mice were used at 6–8 weeks. All mice were bred and maintained under specific pathogen-free conditions at the Walter and Eliza Hall Institute animal breeding facility according to institute guidelines.

Bone marrow cultures

Bone marrow cells were extracted, and erythrocytes were removed by brief exposure to 0.168 M NH₄Cl. Cells were cultured at a density of 1.5 × 10⁶ cells/ml in mouse osmolarity RPMI 1640 medium with 10% (vol/vol) fetal bovine serum containing mouse Flt3L (100 ng/ml, Peprotech) at 37°C in 10% CO₂ (Naik *et al*, 2005). In some cases, GM-CSF (200 ng/ml, R&D Systems) was added to FLT3L cultures 2 days before analysis.

Isolation of DC and DC precursors from spleen, thymus, LN and bone marrow

Spleens or LNs were chopped, then were digested for 20 min at 25°C with collagenase and DNase then treated for 5 min with EDTA to disrupt T cell–DC complexes (Vremec *et al*, 2000; Henri *et al*, 2001). Light-density cells were isolated from cell suspensions using Nycodenz density (spleen 1.076 g/cm³, LN 1.082 g/cm³ and thymus 1.086 g/cm³) and were centrifuged at 1700 g for 10 min at 4°C. The light-density cells were collected, counted and washed, then depleted of non-DC lineages before staining for analysis (Henri *et al*, 2001). Precursor DCs were isolated from BM and spleen as previously described (Liu and Nussenzweig, 2010).

Flow cytometric staining

DC was stained with varying combinations of mAbs to CD11c (HL3), CD45RA (14.8), CD11b (M1/70), CD24 (M1/69), CD4 (GK1.5), CD8 (53-6.7), signal regulatory protein (SIRP)- α (p84), CD103 (M290), CD24 (M1/69), MHC II (M5/114) and Ly5.2 (104). Cells not of the DC lineage and dead cells were excluded by staining for CD19 (ID3), NK1.1 (NKR.PIC), CD3 ϵ (17A2) and propidium iodide. Some samples were stained with anti-Annexin V (BD Biosciences) according to the manufacturer's instructions. Cell sorting and analysis were performed on a FACSVantage^{SE} DiVa, LSRII or FACScan instruments (BD Instruments).

OVA-coated spleen cells

To prepare cell-associated OVA, bm1 spleen cells were γ -irradiated (1000 rads), washed and incubated with 10 mg/ml OVA in RPMI 1640 medium for 10 min at 37°C then washed (Li *et al*, 2001).

Antigen presentation to naive T cells in vitro

In all, 2–2.5 × 10⁴ purified DC subsets were washed and resuspended in 200 μ l mouse tonicity complete RPMI 1640 medium containing 2 × 10⁵ OVA-coated irradiated bm1 splenocytes and 1 × 10⁵ CFSE-labelled OT-I or OT-II T cells. After 60 h culture, T cells were stained for CD8 α or CD4 and proliferation was analysed by flow cytometry as previously described (Belz *et al*, 2002).

Proliferation of DCs

At 5 and 7 days after the initiation of Flt3L-stimulated bone marrow cultures from *Id2^{gfp/gfp}* and *Id2^{gfp/gfp} × Batf3^{-/-}* mice, cells were pulsed with BrdU (3 mg/ml) for 4 h and DC subsets identified as previously described by staining for CD11c, CD45RA and CD103. Cells were fixed with 2% paraformaldehyde and permeabilized 0.1% Tween-20 for 72 h, treated with 100 μ g/ml DNase (Sigma) for 2 h at 37°C and stained with anti-BrdU mAb (Invitrogen) for 40 min then analysed by flow cytometry.

Real-time PCR analysis

Total RNA was prepared from flow cytometrically purified DCs using an RNeasy kit (Qiagen). cDNA was synthesized from total RNA with random hexamers and SuperScript III reverse transcriptase (Invitrogen) or oligo dT using Thermoscript (Invitrogen) RT-PCR system. Real-time PCR of *Hprt*, GFP and *Id2* was performed using the QuantiTect SYBR Green PCR kit (Qiagen) or GoTaq qPCR Master Mix (Promega) as per manufacturers' instructions combined with both the forward and reverse primers for the gene of interest and were measured using the ABI7900HT (Applied Biosystems). Primers for *Id2* were obtained from Applied Biosystems Taqman Gene Expression Assays (Probe Mm_00711781_m1) or as described below. Primer sequences are as follows:

Irf8: 5'-CAG GAG GTG GAT GCT TCC ATC-3'
5'-GCA CAG CGT AAC CTC GTC TTC-3';
Batf3: 5'-CAG AGC CCC AAG GAC GATG-3'
5'-GCA CAA AGT TCA TAG GAC ACA GC-3';
Id2: 5'-ATG AAA GCC TTC AGT CCG GTG-3'
5'-AGC AGA CTC ATC GGG TCGT-3';
Hprt: 5'-GGG GGC TAT AAG TTC TTT GC-3'
5'-TCC AAC ACT TCG AGA GGT CC-3';
GFP: 5'-AGT CCG CCC TGA GCA AAG A-3'
5'-TCA CGA ACT CCA GCA GGA CC-3'.

Analyses were performed in triplicate and the mean normalized expression calculated using the Q-Gene application with *Hprt* serving as a reference gene.

Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

Acknowledgements

We thank Ken Murphy for providing the *Batf3^{-/-}* mice; Frank Batty, Vicki Lapatis and David Baloyan for cell sorting; Elaine Major, Tara Carle and Liana Mackiewicz for expert animal care; and Lorraine O'Reilly and Sarah Oraki for technical advice. This work was supported by grants and fellowships from the National Health

and Medical Research Council of Australia (GTB, SLN, LW and GKS), the Australian Research Council Future Fellowship (AK), Swiss National Science Foundation (FM), the Sylvia and Charles Viertel Foundation and the Howard Hughes Medical Institute (GTB) and the Pfizer Australia Research Fellowship (SLN).

Author contributions: JTJ, FM, AD, SC, AX, MJC, AMM, AK, LW, SN and GTB designed and performed research; JTJ, JH, CL and GKS analysed gene expression data; GTB and SN prepared an initial

draft based on a systematic review of published literature, and discussed the draft with JTJ, FM, AD, SC, AX, MJC, AMM, AK, LW and GKS.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Aliberti J, Schulz O, Pennington DJ, Tsujimura H, Reis e Sousa C, Ozato K, Sher A (2003) Essential role for ICSBP in the *in vivo* development of murine CD8alpha + dendritic cells. *Blood* **101**: 305–310
- Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, Heath WR, Carbone FR (2003) Epidermal viral immunity induced by CD8alpha + dendritic cells but not by Langerhans cells. *Science* **301**: 1925–1928
- Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM (2008) Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. *Immunity* **29**: 795–806
- Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW, Henn V, Kloetzel PM, Gurka S, Kroczeck RA (2010) Superior antigen cross-presentation and XCR1 expression define human CD11c + CD141 + cells as homologues of mouse CD8 + dendritic cells. *J Exp Med* **207**: 1273–1281
- Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. *Immunol Cell Biol* **76**: 34–40
- Belz GT, Behrens GM, Smith CM, Miller JF, Jones C, Lejon K, Fathman CG, Mueller SN, Shortman K, Carbone FR, Heath WR (2002) The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. *J Exp Med* **196**: 1099–1104
- Belz GT, Smith CM, Eichner D, Shortman K, Karupiah G, Carbone FR, Heath WR (2004) Cutting edge: conventional CD8 alpha + dendritic cells are generally involved in priming CTL immunity to viruses. *J Immunol* **172**: 1996–2000
- Carbone FR, Bevan MJ (1990) Class I-restricted processing and presentation of exogenous cell-associated antigen *in vivo*. *J Exp Med* **171**: 377–387
- Carotta S, Dakic A, D'Amico A, Pang SH, Greig KT, Nutt SL, Wu L (2010) The transcription factor PU.1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. *Immunity* **32**: 628–641
- Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Locksley R, Holmberg D, Zweier C, den Hollander NS, Kant SG, Holter W, Rauch A, Zhuang Y, Reizis B (2008) Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. *Cell* **135**: 37–48
- Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset AK, Marvel J, Boudinot P, Hosmalin A, Schwartz-Cornil I, Dalod M (2010) The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha + dendritic cells. *J Exp Med* **207**: 1283–1292
- den Haan JM, Bevan MJ (2002) Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells *in vivo*. *J Exp Med* **196**: 817–827
- Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, Hutloff A, Mages HW, Ranke K, Schaefer M, Jack RS, Henn V, Kroczeck RA (2009) Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8 + T cells. *Immunity* **31**: 823–833
- Dzionic A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. *J Immunol* **165**: 6037–6046
- Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, Klekotka PA, Moon C, Albring JC, Ise W, Michael DG, Bhattacharya D, Stappenbeck TS, Holtzman MJ, Sung SS, Murphy TL, Hildner K, Murphy KM (2010) Peripheral CD103 + dendritic cells form a unified subset developmentally related to CD8alpha + conventional dendritic cells. *J Exp Med* **207**: 823–836
- Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. *Science* **327**: 656–661
- Ginhoux F, Liu K, Helft J, Bogunovic M, Greter M, Hashimoto D, Price J, Yin N, Bromberg J, Lira SA, Stanley ER, Nussenzweig M, Merad M (2009) The origin and development of nonlymphoid tissue CD103 + DCs. *J Exp Med* **206**: 3115–3130
- Hacker C, Kirsch RD, Ju X-S, Heironymous T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M (2003) Transcription profiling identifies Id2 function in dendritic cell development. *Nat Immunol* **4**: 380–386
- Hamilton JA, Anderson GP (2004) GM-CSF biology. *Growth Factors* **22**: 225–231
- Henri S, Vremec D, Kamath A, Waithman J, Williams S, Benoist C, Burnham K, Saeland S, Handman E, Shortman K (2001) The dendritic cell populations of mouse lymph nodes. *J Immunol* **167**: 741–748
- Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM (2008) Batf3 deficiency reveals a critical role for CD8alpha + dendritic cells in cytotoxic T cell immunity. *Science* **322**: 1097–1100
- Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. *Cell* **76**: 17–27
- Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkernagel RM, Morse III HC, Ozato K, Horak I (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* **87**: 307–317
- Honda K, Mizutani T, Taniguchi T (2004) Negative regulation of IFN-alpha/beta signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells. *Proc Natl Acad Sci USA* **101**: 2416–2421
- Ichikawa E, Hida S, Omatsu Y, Shimoyama S, Takahara K, Miyagawa S, Inaba K, Taki S (2004) Defective development of splenic and epidermal CD4 + dendritic cells in mice deficient for IFN regulatory factor-2. *Proc Natl Acad Sci USA* **101**: 3909–3914
- Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ (2010) Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. *J Exp Med* **207**: 1247–1260
- King IL, Kroenke MA, Segal BM (2010) GM-CSF-dependent, CD103 + dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. *J Exp Med* **207**: 953–961
- Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG (2009) The concerted action of GM-CSF and Flt3-ligand on *in vivo* dendritic cell homeostasis. *Blood* **114**: 835–843
- Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR (2001) Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin *in vivo*. *J Immunol* **166**: 6099–6103
- Liu K, Nussenzweig MC (2010) Origin and development of dendritic cells. *Immunol Rev* **234**: 45–54
- Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, Chu FF, Randolph GJ, Rudensky AY, Nussenzweig M (2009) *In vivo* analysis of dendritic cell development and homeostasis. *Science* **324**: 392–397

- Merad M, Manz MG (2009) Dendritic cell homeostasis. *Blood* **113**: 3418–3427
- Mount AM, Smith CM, Kupresanin F, Stoermer K, Heath WR, Belz GT (2008) Multiple dendritic cell populations activate CD4+ T cells after viral stimulation. *PLoS One* **3**: e1691
- Naik SH, Metcalf D, van Nieuwenhuijze A, Wicks I, Wu L, O’Keeffe M, Shortman K (2006) Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. *Nat Immunol* **7**: 663–671
- Naik SH, Proietto AI, Wilson NS, Dakic A, Schnorrer P, Fuchsberger M, Lahoud MH, O’Keeffe M, Shao QX, Chen WF, Villadangos JA, Shortman K, Wu L (2005) Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. *J Immunol* **174**: 6592–6597
- Nichogiannopoulou A, Trevisan M, Neben S, Friedrich C, Georgopoulos K (1999) Defects in hemopoietic stem cell activity in Ikaros mutant mice. *J Exp Med* **190**: 1201–1214
- Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. *Immunity* **33**: 464–478
- Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis ESC (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equi. *J Exp Med* **207**: 1261–1271
- Rathinam C, Geffers R, Yucel R, Buer J, Welte K, Moroy T, Klein C (2005) The transcriptional repressor Gfi1 controls STAT3-dependent dendritic cell development and function. *Immunity* **22**: 717–728
- Rawlins EL, Clark CP, Xue Y, Hogan BL (2009) The Id2+ distal tip lung epithelium contains individual multipotent embryonic progenitor cells. *Development* **136**: 3741–3745
- Schiavoni G, Mattei F, Borghi P, Sestili P, Venditti M, Morse III HC, Belardelli F, Gabriele L (2004) ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. *Blood* **103**: 2221–2228
- Schiavoni G, Mattei F, Sestili P, Borghi P, Venditti M, Morse III HC, Belardelli F, Gabriele L (2002) ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. *J Exp Med* **196**: 1415–1425
- Schon MP, Schon M, Warren HB, Donohue JP, Parker CM (2000) Cutaneous inflammatory disorder in integrin alphaE (CD103)-deficient mice. *J Immunol* **165**: 6583–6589
- Steinman RM, Idoyaga J (2010) Features of the dendritic cell lineage. *Immunol Rev* **234**: 5–17
- Suzuki S, Honma K, Matsuyama T, Suzuki K, Toriyama K, Akitoyo I, Yamamoto K, Suematsu T, Nakamura M, Yui K, Kumatori A (2004) Critical roles of interferon regulatory factor 4 in CD11bhighCD8alpha- dendritic cell development. *Proc Natl Acad Sci USA* **101**: 8981–8986
- Taylor P, Tamura T, Morse III HC, Ozato K (2008) The BXH2 mutation in IRF8 differentially impairs dendritic cell subset development in the mouse. *Blood* **111**: 1942–1945
- Tamura T, Taylor P, Yamaoka K, Kong HJ, Tsujimura H, O’Shea JJ, Singh H, Ozato K (2005) IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. *J Immunol* **174**: 2573–2581
- Vremec D, Pooley J, Hochrein H, Wu L, Shortman K (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. *J Immunol* **164**: 2978–2986
- Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K, Nussenzweig M (2008) The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. *Nat Immunol* **9**: 676–683
- Wu L, Liu YJ (2007) Development of dendritic-cell lineages. *Immunity* **26**: 741–750



The EMBO Journal is published by Nature Publishing Group on behalf of European Molecular Biology Organization. This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. [<http://creativecommons.org/licenses/by-nc-sa/3.0/>]